Advanced search
Publication Cover
Emerging Microbes & Infections Volume 12, 2023 - Issue 1
Submit an article Journal homepage
1,110
Views
0
CrossRef citations to date
0
Altmetric
Coronaviruses

Application of “B+1” heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines

Zezhong Liua Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, School of Pharmacy, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
,
Lu Lua Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, School of Pharmacy, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaView further author information
&
Shibo Jianga Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, School of Pharmacy, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Article: 2192817 | Received 15 Jan 2023, Accepted 14 Mar 2023, Published online: 03 Apr 2023

References

  • Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2022 Dec 14;86(2):279–286.
  • Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2022 Dec 19;614(7948):521–529.
  • Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2022 Dec 6;29(2):344–347.
  • Wang S, Parker C, Taaffe J, et al. Heterologous HA DNA vaccine prime–inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine. 2008 Jul 4;26(29-30):3626–3633.
  • Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009 Jun;21(3):346–351.
  • Jin L, Tang R, Wu S, et al. Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial. Emerg Microbes Infect. 2023 Dec;12(1):2155251.
  • Marks PW, Gruppuso PA, Adashi EY. Urgent need for next-generation COVID-19 vaccines. JAMA. 2023 Jan 3;329(1):19–20.
  • Liu Z, Zhou J, Xu W, et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Res. 2022 Mar;32(3):269–287.
  • Liu Z, Chan JF, Zhou J, et al. A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant. Cell Res. 2022 May;32(5):495–497.
  • Zhou J, Liu Z, Zhang G, et al. Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-beta-coronavirus vaccines. J Med Virol. 2022 Sep 25;95(1):e28172.
  • Pang W, Lu Y, Zhao YB, et al. A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein. Cell Res. 2022 Dec;32(12):1068–1085.
  • Zhao Y, Ni W, Liang S, et al. Vaccination with S(pan), an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice. Sci Transl Med. 2023 Jan 4;15(677):eabo3332.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.